Supernus Pharmaceuticals Holds Special Stockholder Meeting
Supernus Pharmaceuticals shareholders adopted the merger agreement with Indivior at a special meeting on October 15, 2026. Under the agreement, Artemis Merger Sub would merge into Supernus, leaving Supernus as a wholly owned subsidiary of Indivior. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001356576-26-000040), on October 15, 2026, and is solely responsible for the information contained therein. (C)
Story updates
Supernus Pharmaceuticals shareholders adopted the merger agreement with Indivior at a special meeting on October 15, 2026. Under the agreement, Artemis Merger Sub would merge into Supernus, leaving Supernus as a wholly owned subsidiary of Indivior. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001356576-26-000040), on October 15, 2026, and is solely responsible for the information contained therein.
(C)